Analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Atyr PHARMA in a research report issued on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid ...
Leerink initiated coverage of aTyr Pharma with an Outperform rating and $16 price target. The firm has strong confidence aTyr’s lead program efzofitimod will be successful in its ongoing Phase 3 study ...
Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research note issued to ...
Hosted on MSN3d
Leerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform RecommendationFintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...
4d
Leerink Partners analyst Faisal Khurshid initiated coverage on aTyr Pharma Inc ATYR with an Outperform rating and announced a ...
Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...
Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback